First implants for ELA's pacemaker and defibrillator:
This article was originally published in Clinica
ELA Medical has announced the first implants of two of its cardiac devices. The Chorum 7434 VDDR pacemaker, which is indicated for isolated AV block with normal sinus function, has been implanted in Italy. Chorum will be launched after clinical evaluation in Europe ends in January 1998. The first implant of Defender II, ELA's second-generation, dual-chamber defibrillator, has been made at the University Hospital of Rennes in France. The world market for implantable cardiac defibrillators grew from $145 million in 1990 to $780 million in 1996.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.